Integra LifeSciences Holdings Corporation (IART) Stock Forecast
IART analyst forecast
as of October 18, 2026- Analyst consensus
- Hold 3.25 / 5 from 12 analysts
- Price target
- $18.00 average of analyst targets
- Upside to target
- +36.3% from the latest close
- Next earnings
- October 21, 2026 EPS estimate $0.56
- 52-week range
- $8.90 – $19.85
IART analyst ratings
12 analystsNumber of analysts at each rating.
IART price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
IART earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.56 | $0.55 | $0.57 | $0.54 | +3.5% | 10 |
| Current fiscal year (2026) | $2.38 | $2.34 | $2.45 | $2.23 | +6.7% | 9 |
| Next fiscal year (2027) | $2.52 | $2.30 | $2.68 | $2.38 | +5.8% | 12 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
IART revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $412.1M | $410.1M | $416.6M | +2.5% | 9 |
| Current fiscal year (2026) | $1.66B | $1.64B | $1.67B | +1.3% | 10 |
| Next fiscal year (2027) | $1.71B | $1.68B | $1.75B | +3.1% | 11 |
IART EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
IART revenue: reported and forecast
IART EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.56 | $0.56 | $0.56 | $0.56 | $0.56 | −0.0% | 1 up · 2 down |
| Current fiscal year (2026) | $2.45 | $2.46 | $2.46 | $2.40 | $2.38 | −2.8% | 0 up · 3 down |
| Next fiscal year (2027) | $2.62 | $2.61 | $2.61 | $2.59 | $2.52 | −3.8% | 0 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
IART earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; IART beat in 9 of 12.
What analysts expect from IART
12 analysts cover Integra LifeSciences; their consensus rating is hold (3.25 on a 1–5 scale, where 5 is a strong buy). The average price target is $18.00, 36.3% above the latest close of $13.21. Analysts expect earnings of $2.38 per share for 2026, +6.7% from a year earlier. For 2027 the average estimate is $2.52 per share on revenue of $1.7 billion. Integra LifeSciences beat the EPS estimate in 9 of the last 12 quarters.
Related: IART income statement, IART key metrics, IART chart. See the IART stock overview for the latest quote and news.
IART forecast FAQ
What is Integra LifeSciences's price target?
The average analyst price target for Integra LifeSciences is $18.00, 36.3% above the latest close of $13.21.
Is Integra LifeSciences a buy, hold or sell?
Of 12 analysts covering Integra LifeSciences, 2 rate it a strong buy, 1 a buy, 7 a hold, 2 a sell and 0 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
What is Integra LifeSciences's EPS forecast?
Analysts forecast $2.38 per share for 2026 (range $2.34 to $2.45); for 2027 the estimate is $2.52.
What is Integra LifeSciences's revenue forecast?
The average revenue estimate for 2026 is $1.7 billion, growth of 1.3%; for 2027 it is $1.7 billion.
When does Integra LifeSciences report earnings?
Integra LifeSciences is expected to report results for the quarter ending September 30, 2026 on October 21, 2026 before the market opens; the EPS estimate is $0.56.
Does Integra LifeSciences usually beat earnings estimates?
Integra LifeSciences reported EPS at or above the analyst estimate in 9 of the last 12 quarters.